Physician profile
Theodore Ende
NPI 1093722480
$2,320.99
in general payments reported to CMS, 2019-2025
20 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.19 · 2020: $115 · 2021: $88.14 · 2022: $262 · 2023: $746 · 2024: $872 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,763.38 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $993.85 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Kowa Pharmaceuticals America, INC. | $424.98 | 2019-2025 | Seglentis, Livalo, Zoryve |
| Amgen INC. | $168.59 | 2023-2024 | Repatha, Otezla, Krystexxa |
| Exact Sciences Corporation | $108.78 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $91.47 | 2023-2024 | Trelegy Ellipta |
| Stryker Corporation | $71.87 | 2023 | Blueprint Patient Specific Instrumentation, Aequalis Perform Reversed |
| Medtronic, INC. | $61.87 | 2021-2025 | Closurefast |
| Novartis Pharmaceuticals Corporation | $61.86 | 2022 | |
| Pfizer INC. | $58.96 | 2019-2023 | |
| Lilly USA, LLC | $56.55 | 2019-2024 | Jardiance, Mounjaro |
| Dexcom, INC. | $53.47 | 2022-2023 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $33.95 | 2024-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.22 | 2020-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $18.39 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.00 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $14.93 | 2022 | |
| Abbott Laboratories | $14.74 | 2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $14.49 | 2020 | |
| Sunovion Pharmaceuticals INC. | $13.86 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.16 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Ende listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.